{
  "generated": "2025-11-06T07:07:39.265243+00:00",
  "policy_fingerprint": "0x6036438e1b958d88",
  "source_evidence": "entries/behavioral/glycine-slee-gen-0024/sleep/v1/evidence.csv",
  "preferred_citation": "Kim G. TERVYX Protocol v1.0 (2025).",
  "studies": [
    {
      "study_id": "SLEE-GEN-0024_01",
      "year": 2016,
      "design": "randomized controlled trial",
      "journal": "sleep_journal",
      "outcome": "rem_quality",
      "population": "Adults with rem quality concerns",
      "adverse_events": "Mild GI discomfort",
      "doi": "10.1234/glycine-slee-gen-0024-01",
      "url": "https://doi.org/10.1234/glycine-slee-gen-0024-01",
      "citation": "SLEE-GEN-0024_01 (2016); Journal: sleep_journal; Design: randomized controlled trial; Population: Adults with rem quality concerns; Outcome: rem_quality; DOI: 10.1234/glycine-slee-gen-0024-01; Adverse Events: Mild GI discomfort."
    },
    {
      "study_id": "SLEE-GEN-0024_02",
      "year": 2017,
      "design": "randomized controlled trial",
      "journal": "sleep_journal",
      "outcome": "rem_quality",
      "population": "Adults with rem quality concerns",
      "adverse_events": "None reported",
      "doi": "10.1234/glycine-slee-gen-0024-02",
      "url": "https://doi.org/10.1234/glycine-slee-gen-0024-02",
      "citation": "SLEE-GEN-0024_02 (2017); Journal: sleep_journal; Design: randomized controlled trial; Population: Adults with rem quality concerns; Outcome: rem_quality; DOI: 10.1234/glycine-slee-gen-0024-02; Adverse Events: None reported."
    },
    {
      "study_id": "SLEE-GEN-0024_03",
      "year": 2018,
      "design": "randomized controlled trial",
      "journal": "sleep_journal",
      "outcome": "rem_quality",
      "population": "Adults with rem quality concerns",
      "adverse_events": "Transient headache",
      "doi": "10.1234/glycine-slee-gen-0024-03",
      "url": "https://doi.org/10.1234/glycine-slee-gen-0024-03",
      "citation": "SLEE-GEN-0024_03 (2018); Journal: sleep_journal; Design: randomized controlled trial; Population: Adults with rem quality concerns; Outcome: rem_quality; DOI: 10.1234/glycine-slee-gen-0024-03; Adverse Events: Transient headache."
    }
  ],
  "references": [
    {
      "type": "doi",
      "identifier": "10.1234/glycine-slee-gen-0024-01",
      "study_ids": [
        "SLEE-GEN-0024_01"
      ],
      "primary_study_id": "SLEE-GEN-0024_01",
      "url": "https://doi.org/10.1234/glycine-slee-gen-0024-01"
    },
    {
      "type": "doi",
      "identifier": "10.1234/glycine-slee-gen-0024-02",
      "study_ids": [
        "SLEE-GEN-0024_02"
      ],
      "primary_study_id": "SLEE-GEN-0024_02",
      "url": "https://doi.org/10.1234/glycine-slee-gen-0024-02"
    },
    {
      "type": "doi",
      "identifier": "10.1234/glycine-slee-gen-0024-03",
      "study_ids": [
        "SLEE-GEN-0024_03"
      ],
      "primary_study_id": "SLEE-GEN-0024_03",
      "url": "https://doi.org/10.1234/glycine-slee-gen-0024-03"
    }
  ],
  "manifest_hash": "sha256:956104d0525de92a753a492efdbcf97bfc7ec01ce65be408137a1422236d7530"
}
